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Background and Objective. This study was aimed to analyse the curative eﬀects of Pinellia ternata, Citrus reticulata, and their
combination on airway hyperresponsiveness (AHR) to inhaled methacholine, pulmonary eosinophilic inﬁltration, Th2 cytokine
production, and IgE and histamine production in a murine model of asthma. Methods. For this purpose, BALB/c mice were
systemically sensitized to ovalbumin (OVA) followed intratracheally, intraperitoneally, and by aerosol allergen challenges for 12
weeks. We examined the development of pulmonary eosinophilic accumulation, control of Th2 cytokine, immunoglobulin E
(IgE), and histamine productions in a murine model of asthma. Results. Our data suggest that the therapeutic mechanism by
which Pinellia ternata, Citrus reticulata, and their combinational prescription eﬀectively treats asthma is based on reductions of
eosinophil inﬁltration, eotaxin receptor (CCR3), histamine, OVA-speciﬁc IgE productions in serum, and Th2 cytokines (IL-5, IL-
13) by marked reductions of IL-5 and IL-13 mRNA expression in lung tissue. Conclusions. These ﬁndings provide evidence that
Pinellia ternata, Citrus reticulata, and their combination play a regulatory role in allergic inﬂammation and oﬀer therapeutic
approaches as novel CCR3 antagonists for treatment asthma. However, it is not clear whether pharmacological activities of
prescription composed of two herbs are potentiated due to synergistic eﬀect or additive eﬀect.
Copyright © 2009 In-Soo Ok et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Asthma is a chronic inﬂammatory disease of the airway,
which is characterized by the presence of increased num-
bers of T-helper 2 (Th2) lymphocytes, eosinophils [1],
and airway inﬂammation [2]. It is accompanied by high
serum levels of immunoglobulin E (IgE), as well as by
intrapulmonary production of interleukin-4 (IL-4), IL-5,
and IL-13 by allergen-speciﬁc Th2 cells [3]. Airway inﬂam-
mation is associated with the inﬁltration of eosinophils,
neutrophils, and T and B lymphocytes into airway and lung
tissues.
In most asthma phenotypes, there are increases in
eosinophils in the tissues, blood and bronchoalveolar lavage
ﬂuid. Moreover, Th2 cells and their secreted products initiate
airway inﬂammation that begins with the inﬁltration of
eosinophils and other inﬂammatory cells. The recruited
eosinophils produce IL-3, IL-5, IL-6, IL-13, and so forth.
Th2 cytokines play an important role in the lungs
of asthmatic subjects, particularly because IL-4 and IL-13
enhanceimmunoglobulin E(IgE)production,IL-5enhances
eosinophil accumulation, and IL-13 directly enhance mucus
hypersecretion and airway hyperreactivity (AHR) [4, 5].
Pinellia ternata (PT), Citrus reticulata (CR), and their
combinational prescription (composed of PT, CR by a ratio
of 50 to 50 based on Korean traditional medicinal formulae)
are medicinal herbs and prescription (Leejintang) that
have been used for treating airway inﬂammatory deseases
(including asthma) in Korea [6]. PT has the actions of
relieving cough, antiemetic, antineoplasm, antifertilization.2 Mediators of Inﬂammation
Previous studies reported that guanosine, tyrosine, and
phenylalanine were contained in the tuber of PT [7].
Recently, cytidine, adenosine, tryptophan, uridine, and ade-
nine are reported to be contained for the ﬁrst time in the
tuber of PT by Chen et al. [8].
Pinellic acid (9S, 12S,13S-trihydroxy-10E-octadecenoic
acid) has been identiﬁed as an orally active adjuvant
substance from the tuber of PT [9]. In addition, pinellic acid
modulate the production of antigen-speciﬁc antibodies in
therespiratorytractsandOraladministrationofpinellicacid
(50μg/kg/day) also reduced the OVA-speciﬁc IgE antibody
titer in BAL ﬂuids from the sensitized mouse [10].
CR is consisted of component such as ﬂavonoids,
limonoid, polyphenols. Among those, ﬂavonoids aﬀected
the inﬂammation response at human monocytes and citrus
nobiletin had inhibitory eﬀect on the reduction of phor-
bol ester-induced skin inﬂammation [11–13]. Jung et al.
reported that CR-inhibited expression of iNOS and NF-kB
activation in LPS-activated RAW 264.7 macrophage cells
[14]. Hesperidin [15] of which exhibit antiinﬂammatory
eﬀects, are the active ingredients in Citrus ﬂavonoid.
However, there have been no reports of the antiasth-
matic and antiinﬂammatory activities of PT, CR and their
combinational prescription in vivo. The aim of this study
was to evaluate the ability of them to control Th2-type
cytokines,eosinophilinﬁltrationandotherfactors.Ourﬁnd-
ings provide evidence that PT, CR and their combinational
prescription play a regulatory role in allergic inﬂammation
and oﬀer therapeutic approaches as novel CCR3 antagonists
for treatment asthma.
2.MaterialsandMethods
2.1. Plant Material and Preparation of Extracts. The tuber of
PT, CR and their combinational prescription were purchased
from Saerom company (Ansung, South Korea) in February,
2006. The plant was identiﬁed by Professor Young-Cheol
Lee, College of Oriental Medicine, Sangji University in
Wonju, South Korea, and a voucher specimens (PT, CR)
are deposited in our laboratory (Department of Herbology,
College of Oriental Medicine, Sangji University Wonju 220–
702, South Korea). Plant materials (PT, 200g; CR, 200g;
prescription, 200g) was extracted three times with 1.5
liter of distilled water at 100◦C for 2 hours separately.
Then, the extract was ﬁltered and evaporated on a rotatory
evaporator (Rotary evaporator, BUCHI B-480, Switzerland)
and ﬁnally dried by a freeze drier (Freeze dryer, EYELA
FDU-540, Japan) to yield the extract PT (20g), CR (15g)
and their combinational prescription (18g).The yield (w/w)
of the extract was about 10% (PT), 7.5% (CR) and 9%
(PT+CR).
2.2. Animals. Seven to eight-week-old female Balb/c mice
were obtained from Daehan Biolink Co. LTD. (Eumsung,
South Korea). All animal procedures were conducted in
accordance with the guidelines of the Institutional Animal
Care and Use Committee of the South Korea Research
Institute of Bioscience and Biotechnology (Daejeon, South
Korea).
2.3. Ovalbumin (OVA) Sensitization and Inhalation. As per
the modiﬁed protocol previously described [16, 17], OVA
(500μg/mL) in PBS was mixed with equal volumes of
10%(w/v) aluminum potassium sulfate (alum; Sigma) in
distilled water, then incubated for 60 minutes at room tem-
perature after adjustment to pH 6.5 using 10NNaOH, and
centrifuged at 750 × g for 5 minutes. The OVA/alum pellet
was resuspended to the original volume in distilled water. All
mice were immunized on two diﬀerent days (21 days and 7
days before inhalational exposure) by intraperitoneal (i.p.)
injections of 0.2mL alum-precipitated antigen containing
100μgofOVA(Sigma-AldrichKorea,SouthKorea)boundto
4mg of aluminum hydroxide (Sigma-Aldrich Korea. South
Korea) in PBS. Seven days after the second sensitization,
mice were exposed to aerosolized OVA for 30 minutes/day,
3d a y s / w e e kf o r1 2w e e k s( a taﬂ o wr a t eo f2 5 0L / m i n u t e s ,
2.5%OVAinnormalsaline)andintratracheallyinjectedwith
250μg of OVA (on day 8) on the back of the tongue. PT,
CR and their mixture (200, 400mg/kg) and cyclosporin A
(CsA, 20mg/kg) in solution form were orally administered 3
times a week during the last 8 weeks. One day after the last
OVA exposures, airway hyperresponsiveness was determined
and samples (blood, bronchoalveolar lavage ﬂuid, lung cells,
spleen, peripheral blood mononuclear cells and serum) were
collected for further analyses. Blood leukocyte and diﬀer-
ential counts were determined by automatic blood count
analysis.
2.4. Determination of Airway Hyperresponsiveness (AHR).
Airway hyperresponsiveness in mice was estimated using a
previously described method with modiﬁcations [17, 18].
A Buxco system (Biosystem XA; Buxco Electronics Inc,
Troy, Conn, USA) was used to evaluate the extent of
airway constriction in diﬀerent groups of mice following the
protocol described previously.
Enhanced pause (Penh) is equal to Pause × PEF/PIF,
where Pause = (Te − Tr)/Tr (PIF, peak inspiratory ﬂow;
PEF: peak expiratory ﬂow; Te, expiratory time; Tr, relaxation
time). In this experiment, mice were aerosolized with
OVA for 30 minutes/day, 3 days/week for 12 weeks. At
24 hours after the ﬁnal inhalation, the mice were given
aerosolized normal saline, followed by 3.125, 6.25, 12.5, 25,
50mg/mL methacholine (Sigma) serially. Airway reactivity
was then monitored for 30 minutes. Diﬀerences of Penh
value between groups were evaluated using a Student’s
t-test.
2.5. Bronchoalveolar Lavage Fluid (BALF). Immediately fol-
lowing assessment of AHR, mice were sacriﬁced with an
i.p. injection of sodium pentoparbitone (100mg/kg). The
trachea was cannulated and BAL ﬂuid were obtained by
washing the airway lumina. Brieﬂy, cells in the lungs were
recovered by ﬂushing 1mL of BAL ﬂuid (1mM EDTA, 10%
FBS, PBS) into the lungs via the trachea. Total cell counts
were determined and 100μl of ﬂuid was cytospun onto glass
slides using a Cytospin centrifuge (Cellspin, Hanil,, South
Korea) (400g for 4 minutes). Diﬀerential cell counts were
performed after staining with a Diﬀ-Quik Stain Set (Baxter
Healthcare Corp., Miami, Florida, USA). The supernatant ofMediators of Inﬂammation 3
BALF was stored at −25◦C for Determination of cytokine
levels.
2.6. Digestion of Pulmonary Tissue and Cell Preparation.
Single cell suspensions from lung tissues and BALF were
isolated by mechanical disruption in RPMI 1640 medium
supplemented with 2mM L-glutamine, 100U/mL penicillin,
100μg/mL streptomycin, 50μM 2-mercaptoethanol, 20mM
HEPES, and 2% heat-inactivated fetal bovine serum (FBS,
GIBCO, Grand Island, NY, USA). Brieﬂy, the lungs were
removed from thoracic cavity. After mincing using sterile
scalpels,thetissuewasincubatedinPBScontaining1mg/mL
collgenase IV and 2mg/mL dispase for 40 minutes at 37◦C
in a sterile polypropylene tube. After incubation, lung
tissue was vigorously pipetted up and down to further
dissolve remaining tissue clumps and then ﬁltered using
a7 0 μm cell-strainer (Falcon, Le Pont de Claix, France).
The total number of cells was counted manually using a
hemocytometerchamber(Fisher).Between2and4×103 cells
were spun onto glass slides (Cytospin centrifuge,Cellspin,
Hanil, South Korea) (400g for 4 minutes). Diﬀerential
counts were done according to standard morphologic
criteria.
An amount of 10 IU sodium-heparin dissolved in 1 × D-
PBS (with Ca2+ and Mg2+) were used per milliliter of blood
from mice. Peripheral blood mononuclear cells (PBMCs)
were isolated by centrifugation on Ficoll (density 1.077).
They were washed 2 × with D-PBS (with Ca2+ and Mg2+)
and used for FACS analysis.
2.7. Antibodies and Flow Cytometric Analysis. All antibodies
(such as CD3, CCR3, Gr-1, CD11b) to study cell surface
markers for diﬀerent types of leukocytes including T cells
(CD3), eosinophil (CCR3), granulocytes (Gr-1) for ﬂow
cytometric analysis were purchased from Becton Dickinson
(BD) PharMingen (San Diego, Calif, USA). Cells from lung
tissues and BALF were stained with the indicated antibodies
instainingbuﬀer(PBScontaining1%FBSand0.01%NaN3)
for 10 minutes on ice, and analyzed by two color ﬂow
cytometry on a FACSCalibur using CellQuest software (BD
Biosciences, Mountain View, Calif, USA).
2.8. QuantitativeReal-Time PCR. To study the antiasthmatic
eﬀects of PT, CR and their combinational prescription on
cytokine gene expression from lung tissue, quantitative real-
time PCR was performed after quantitative normalization
for each gene by densitometry using β-actin gene expres-
sion. Brieﬂy, total cellular RNA was extracted from the
lung by the phenol-chloroform based method (RNAsol
B:
Tel-Test Co. Ltd, USA) according to the manufacturer’s
instructions. cDNA was synthesized from 3 μgo ft o t a l
RNA using a ReverTraAce-a-cDNA Synthesis kit (Toyobo
Co., Ltd. Osaka, Japan) according to the manufacturer’s
instructions. Real-Time quantitative PCR was performed
using the Applied Biosystems 7500 Fast Real-Time PCR
system (Applied Biosystems, USA) with the following
primers.
The primer sequences are as follows: mouse IL-5, 5 -
AACCCTTACTGAACTCAGATTGTTAG-3  and 5 -TAA-
GTCAGTTTAAATGCTTAGGG-3  IL-13, 5 -ATGCCC-
AACAAAGCAGAGAC-3  and 5 -TGAGAGAACCAGGGA-
GCTGT-3 β-actin, 5 -TGGAATCCTGTGGTCCATGAA-
AC-3  and 5 -GTCACAGTCAGCTGTATAGGG-3 .
Proinﬂammatory cytokine gene expression was analyzed
with SYBR Green PCR Mastermix (ABI) and a ﬁnal con-
centration of 200nM primers, using β-actin as the internal
standard. The following PCR parameters were used: 2
m i n u t e sa t5 0 ◦C, 10 minutes 94◦C, then 40 cycles of 1
minute at 94◦C, and 1 minutes at 60◦C. The amount of
SYBR Green was measured at the end of each cycle. The cycle
number at which the emission intensity of the sample rose
above baseline was referred to as the (relative quantitative)
RQ and was proportional to the target concentration. Real-
Time PCR was performed in duplicate and analyzed by a
AppliedBiosystems7500FastReal-TimePCRsystemmanual
(threshold: 0.05, baseline: 6–15 cycles). To generate standard
curves for Proinﬂammatory cytokine and β-actin, serially
diluted cDNA (1/1–1/16) was prepared and Real-Time PCR
was performed as above. RQ evaluation by RT-PCR was
determined and expressed for various samples.
2.9. Enzyme-Linked Immunosorbent Assay (ELISA). Inter-
leukin (IL-4, IL-5, IL-13, eotaxin etc.) and IFN-γ production
from BALF and the serum of the indicated mice (n = 5)
was measured by ELISA according to the manufacturer’s
instructionswithamonoclonalantibody-basedmouseinter-
leukin ELISA kit (R&D system). OVA-speciﬁc IL-4 and
IFN-γ production from spleen cells were suspended in
RPMI 1640 medium supplemented with 2mM L-glutamine,
and 5% fetal bovine serum. The spleen cells were then
cultured for 48 hours at a concentration of 1 × 105 cells/well
in 96-well culture plates (Corning Inc, Cambridge, Mass,
USA) with or without 1μg/mL of OVA in a humidiﬁed
atmosphere of 5% CO2 in air at 37◦C. The culture super-
natants were collected and were assayed for IFN-γ and
IL-4 antibodies induced by OVA using ELISA. All data
representthemeanandstandarddeviationfromatleastthree
separate experiments and were compared using a Student’s
t-test.
2.10. Immunohistochemistry (Hematoxyline-Eosin and Mas-
son Trichrome Staining). Balb/c mice were injected, inhaled
and sprayed with OVA for 12 weeks (three times a week)
to induce asthma induction. The experimental groups
were treated with diﬀerent concentrations of PT, CR and
their combinational prescription for the later 8 weeks (3
times/week). At the end of the experiment, the lungs
were removed and analyzed histologically using a modiﬁed
protocol previously described [19].
2.11. Preparative LC Analysis. The water extract was sepa-
rated by preparative LC (Waters Associates, Milford, Mass,
USA) using a ACE 10 C18 column (250 × 30mm), a model
LKBVWMabsorbancedetectorat214nm,andamodelLKB
2221 integrator. The gradient was solvent B (0 ∼ 3: 100%
in water), solvent A (3 ∼ 20: 0 ∼ 100% acetonitrile), and
solvent A (20 ∼ 30: 100% acetonitrile) for 30 minutes at a
ﬂ o wr a t eo f3 0m L / m i n u t e s .4 Mediators of Inﬂammation
2.12. Statistical Analysis. For statistical analysis of data, P-
values were determined using a one-way analysis of variance
(ANOVA) or unpaired Student’s t-test followed by Dunnett’s
multiple comparison test (SPSS version 14.0 statistic soft-
ware). The diﬀerence between the normal group and the
control group (OVA+vehicle) was clearly distinguished, and
for this reason, statistical signiﬁcance between the normal
group and the control group was not shown in the ﬁgures
and tables to put an emphasis on the statistical diﬀerences
between the experimental groups and the control group.
Results were considered statistically signiﬁcant if P values
were <.05 (∗), <.01 (∗∗), or <.001 (∗∗∗).
3. Results
3.1. Inhibitory Eﬀect of PT, CR, and Their Combinational Pre-
scription on Airway Hyperresponsiveness (AHR). To evaluate
the eﬀect of PT, CR and their combinational prescription
on airway hyperresponsiveness, total pulmonary airﬂow
obstruction in mice was estimated using a mouse asthma
model. Penh was measured using a Buxco system on day
1 after ﬁnal inhalation and samples were immediately
collected. Animals exposed to aerosolized OVA showed
increase AHR compared to animals receiving saline only
(Figure 1(b)). As shown in Figure 1, relative to animals
sensitized with OVA (Control group), PT, CR and their com-
binational prescription (200, 400mg/kg) treatment resulted
in a signiﬁcant decrease in methachoine-induced AHR.
3.2. Histological Analysis of Lung Sections. We found inﬁl-
tration of leukocytes in histologic sections of lungs from
OVA-exposed control mice, and lung tissue sections from
OVA-exposed mice showed airway inﬂammation and ero-
sion. Eosinophil inﬁltration was mainly observed in the
peribronchial regions of the lung. In contrast, histological
sections from herbal extracts-treated mice indicated reduced
airway inﬂammation of lung tissue (Figure 1(c)).
3.3. Inhibitory Eﬀect of PT, CR, and Their Combinational
Prescription on Airway Eosinophil Accumulation and Inﬂux of
Inﬂammatory Cells into Airways. As shown in Figures 2(a)
and 2(c), the total lung cells and total leukocytes in BALF
weresigniﬁcantlyreducedinPT,CRandtheircombinational
prescription-treated mice compared with control mice, and
the number of total spleen cells and lung weight were not
signiﬁcantly reduced in PT, CR and their combinational
prescription-treated mice (Figures 2(b) and 2(d)).
Treatment with PT, CR and their combinational
prescription resulted in signiﬁcantly lower numbers
of eosinophils (Figure 3(a)), neutrophils (Figure 3(a)),
CD3-CCR3+ eosinophils in BALF (Figure 3(b)), spleen
(Figure 3(c)) and PBMC (Figure 3(d)) and Gr-1+CD11b+
substantial portion of eosinophils in lung (Figure 3(e)) than
control group. Neutrophil number in the bronchoalveolar
lavage ﬂuid of mice treated with CR (200mg/kg) was lower
than in immunised mice treated with OVA (Figure 3(a)).
In all groups, eosinophil number in bronchoalveolar lavage
ﬂuid was lower than in immunised mice treated with
OVA. Increased cell inﬁltration in bronchoalveolar lavage
ﬂuid after Ovalbumin challenge was shown in Figure 3(b).
However, PT (200mg/kg) did not aﬀect the absolute number
of CD3-CCR3+ eosinophils in spleen (Figure 3(c)).
3.4. Inhibition of Cytokines (In Vivo and In Vitro), IgE, and
Histamine Production in BAL Fluid and Serum. As shown
in Figure 4(a), IL-4, IL-5, IL-13 and eotaxin levels were
signiﬁcantly reduced in PT, CR and their combinational
prescription-treated mice. However, they did not aﬀect IFN-
γ productions in BALF.
In our study, serum IgE levels from OVA-induced
asthmatic mice were signiﬁcantly increased compared with
control mice (PBS only). PT (400mg/kg), CR (400mg/kg)
and their combinational prescription (200, 400mg/kg) had
signiﬁcantlyreducedthehistamineproduction(Figure 4(c)).
However, only combinational prescription (200, 400mg/kg)
signiﬁcantly reduced the IgE production (Figure 4(c)). We
also measeured IL-4 and IFN-γ in the culture supernatants
were measured by ELISA and found that combinational pre-
scription (400mg/kg) signiﬁcantly inhibited Th2 cytokine
(IL-4) production in splenocytes (Figure 4(d)) which was
accompanied by a concurrent decrease in Th2 cytokine
production in BALF.
3.5. Detection of IL-5, IL-13 mRNA in Lung Tissue by SYBR
Green Real-Time PCR. As shown in Figure 4(b), the mRNAs
for IL-5 and IL-13 were detectable in lung cells treated
with PBS only, OVA, and OVA plus PT, CR and their
combinational prescription (200, 400mg/kg) respectively.
PCRproductsforIL-5andIL-13ampliﬁedfromlungcell
RNA preparations were decreased in the PT, CR and their
combinational prescription-treated mice compared with
control mice (ova-induced asthma model mice group). This
result was accompanied by changes in the eosinophil inﬂux
(CD3−/CCR3+) (Figures 3(b)–3(e)), and BAL cytokines (IL-
4, IL-5, and IL-13) production to some degree.
3.6. Peak Patterns of PT, CR, and Their Combinational
Prescription for Quality Control. PT, CR and their combi-
national prescription were analysed by preparative LC. The
chromatogram of them is shown in Figure 5. Peaks of the
principal components have not yet been identiﬁed in this
study.
4. Discussion
Therapeutic targets that may be used in the treatment of
asthma are numerous. IL-4 blockers either by themselves or
in combination with other anti-Th2 cytokines inhibits IgE
production and eosinophil inﬁltration [20]. Because, IL-5
is both a survival and recruitment factor for eosinophils,
anti-IL-5 antibody therapy reduces eosinophil adhesion,
inﬁltration and mediator release [21]. Eosinophilia is driven
by Th2 cytokines (e.g., IL-4, IL-5, IL-13) produced by
Th2 cells. IL-5 is the most critical cytokine mediating
increased eosinophil diﬀerentiation, maturation, activation,
and survival [22].Mediators of Inﬂammation 5
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Figure 1: (a), Schematic diagram of methacholine-induced AHR in the sensitization protocol. (b), PenH was measured in a Buxco box,
as previously described in materials and methods. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 asthma goup (control) versus PT, CR and their
combinational prescription treated groups. (c), Eﬀect of PT, CR and their combinational prescription on histology of lung tissue (H&E
and M-Tstaining) in lung cells of OVA-induced murine model of asthma. H and E: hematoxylin-eosin stain, M-T: Masson trichrome stain,
The results are expressed the mean ± S.E (N = 5). Statistically signiﬁcant value compared with control group data by ANOVA (∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 001). N: Normal Balb/c mice, CT: Ovalbumin inhalation (control), OVA + CsA (10mg/kg), OVA + PT(200, 400mg/kg),
OVA + CR(200, 400mg/kg), OVA + (PT + CR) (200, 400mg/kg).6 Mediators of Inﬂammation
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Figure 2: Eﬀects of PT, CR and their combinational prescription on total lung cells, total leucocytes, total lung weight, and total spleen cell.
Mice were processed as described in materials and methods, and whole blood was harvested 24 hours after the last OVA challenge. Total
inﬂammatory cell numbers in BALF, lung and spleen were counted, and cell classiﬁcation was performed on a minimum of 200 cells to
classify lymphocytes. The results are expressed the mean ± S.E (N = 5). Statistically signiﬁcant value compared with control group data
by ANOVA or unpaired Student’s t-test (∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001). N: Normal Balb/c mice, CT: Ovalbumin inhalation (control
group), CsA: OVA + CsA (10mg/kg), OVA + PT(200, 400mg/kg), OVA + CR(200, 400mg/kg), OVA + (PT + CR) (200, 400mg/kg).
In this manuscript, we have shown that oral administra-
tion of PT, CR and their combinational prescription soften
up the phenotype of allergic airway inﬂammation in BALB/c
mice.
PT, CR and their combinational prescription prevented
the development of AHR (Figure 1(b)), airway eosinophilia
(Figure 3), increased Th2 cytokines levels (Figures 4(a)
and 4(d)) in BAL ﬂuid and lung inﬂammation. These
results demonstrate that PT, CR and their combinational
prescription has profound negative regulatory eﬀects on
the development of lung allergic responses in OVA-induced
asthmamodelmice.Moreover,thenegativeregulatoryeﬀects
exhibited by them were accompanied by the production of
IL-5,IL-13.
Asthma produces immune abnormalities in a wide vari-
etyofcellpopulations.Thus,anothergoalinasthmaresearch
would be the evaluation of speciﬁc cell subpopulation.
In our immunophenotyping by ﬂow cytometry
showed a similar pattern as total lymphocyte numbers
in BALF and lung. Inhibitory eﬀect of PT, CR and
their combinational prescription were observed at 200,
400mg/kg and hence was used for studying its eﬀect on
CD3-CCR3+ eosinophils in BALF, spleen, PBMC, and
lung.
Eosinophils are attracted, via their CC chemokine recep-
tor 3 (CCR3), in response to chemoattractants such as
eotaxin, Rantes, MCP-3, MCP-4 released in the airways of
asthmatics [23].Mediators of Inﬂammation 7
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Figure 3: Quantiﬁcation by means of FACS analysis of CD3-CCR3+ cell subtypes in BALF, spleen, lung, and PBMC. Absolute number of
CD3-CCR3+ cell subtypes in BALF, spleen, lung and PBMC were counted (seen materials and methods). The results are expressed the mean
± S.E (N = 5). Statistically signiﬁcant value compared with control group data by ANOVA or unpaired Student’s t-test (∗P<. 05, ∗∗P<. 01,
∗∗∗P<. 001). N: Normal Balb/c mice, CT: Ovalbumin inhalation (control group), CsA: OVA + CsA (10mg/kg), OVA + PT(200, 400mg/kg),
OVA + CR(200, 400mg/kg), OVA + (PT + CR) (200, 400mg/kg).8 Mediators of Inﬂammation
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Figure 4: (a), (c), Eﬀect of Pinellia ternata, Citrus reticulata and their combinational prescription on Th2 cytokines (IL-4, IL-5, IL-
13), Th1 cytokine (IFN-γ), eotaxin in BALF and IgE, histamine level in serum. (b), Eﬀect of Pinellia ternata, Citrus reticulata and their
combinational prescription on IL-5, IL-13 mRNA gene expression in lung tissue of OVA-induced murine model of asthma (seen materials
and methods). (d), Immunomodulatory eﬀects of Pinellia ternata, Citrus reticulata and their combinational prescription on OVA-speciﬁc
Th1/Th2 cytokines production in spleen cells (described in materials and methods). The results are expressed the mean ± S.E (N = 5).
Statistically signiﬁcant value compared with control group data by ANOVA or unpaired Student’s t-test (∗P<. 05, ∗∗∗P<. 001). N:
Normal Balb/c mice, CT: Ovalbumin inhalation (control group), CsA: OVA + CsA (10mg/kg), OVA + PT(200, 400mg/kg), OVA + CR(200,
400mg/kg), OVA + (PT + CR) (200, 400mg/kg).
Among chemokines, only CCL11(eotaxin) binds specif-
ically to CCR3 and is the most potent chemokine for
movementofthesecells[24].TheCCR3receptorseemstobe
involved in the activation and degranulation of eosinophils,
aswellaswiththeprimarymigrationofthecells,asanumber
of CCR3 ligands have been reported to induce degranulation
of eosinophils [25].
The airway inﬂammation process that occurs in the
development of asthma is characterized by tissue inﬁltration
of eosinophils.
Similar to what was seen for cell recruitment (Figure 2),
PCR products for IL-5, IL-13 from lung cell RNA prepara-
tions were decreased in the PT, CR and their combinational
prescription treated group compared with control groups.
This results indicate that they signiﬁcantly aﬀected IL-5, IL-
13 mRNAs expression which attract eosinophils and Th2
cells into the airway.
EosinophilsareoneofthecelltypesknowntoexpressGr-
1andtheeosinophilpopulationsmayconstituteasubstantial
portion of the CD11b+Gr-1+ or CD11b+CD49b+Gr-1+Mediators of Inﬂammation 9
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Figure 5:Chromatographicseparationoftheaqueousextractsofcrude(a)PT,(b)CRand(c)theircombinationalprescription,respectively.
Because most of the peaks were eluting within the ﬁrst 30 minutes, the chromatograms are the displays of the up to 30 minutes.
populations [26] that signiﬁcantly decreased in PT, CR and
theircombinationalprescriptiontreatedgroupscomparedto
OVA-challenge (Figure 3(e)).
Our results show that this is the ﬁrst study that examines
the inhibitory eﬀects of PT, CR and their combinational pre-
scription in lung and BALF on OVA-induced murine model
of asthma after inhaled OVA challenge. We observed that
inhalation challenge with PT, CR and their combinational
prescription administration resulted in a decrease in airway
CD11b+ macrophage, Gr-1 granulocytes when compared
withthatobservedafterOVAchallengeonly.Moreover,CD3-
CCR3 expression in BALF, spleen, PBMC is downregulated
by them (Figures 3(b), 3(c),a n d3(d)).
Nicholas reported that T helper (Th) type 2 cytokines
interleukin (IL)-4 and IL-13 induce the production of spe-
ciﬁc chemokines through STAT6 signal activated pathways
[25]. This chemokine (eotaxin/CCL11) induces migration
of Th2 lymphocytes through speciﬁc receptors (CCR3).
Eotaxin, have also been shown to be potent eosinophil
chemoattractants. The continued activation of these cell
populations promotes the chronic pathophysiological dys-
function observed during asthma, including mucous pro-
duction, peribronchial thickening and ﬁbrosis. These path-
ways might be initiated and maintained through chronic
allergen exposure.
Therfore, it may be thought that PT, CR and their com-
binational prescription can reduce Th2 cytokine production
and gene expression by inhibition STAT6 activation by above
similar mechanism.
Pharmaceutical actions, derived from the combination
of herbal formula, are called “chemical combination eﬀects”.
Kiyohara et al. explained that these complex phenomena
a r es u p p o s e dt oe m e r g ea san u m b e ro fd i ﬀerent active
ingredientsinteractwitheachother,actingondiﬀerenttarget
systems in the body. These types of pharmacological action
are called either “pharmacological combination eﬀects” or
“pharmaceutical combination eﬀects” [27]. As shown in our
results, it would be interesting to identify precisely such10 Mediators of Inﬂammation
therapeutic mechanism aﬀected by them in future studies.
Particularly, combinational prescription is more eﬀective in
I L - 1 3a n de o t a x i np r o d u c t i o ni nB A L F( Figure 4(a)), but it is
not certain that above formula has a chemical combinational
eﬀects.
In summary, PT, CR and their combinational prescrip-
tion have deep inhibitory eﬀects on airway inﬂammation in
a murine model of asthma and it was caused by suppression
of Th2 cytokines (IL-4, IL-5, IL-13), IgE, eosinophil CCR3
expression in lung. Hence, the results indicated that they
could act as a potential immunomodulator by downregula-
tion Th2 cytokines. However, additional studies are needed
to characterize the precise mechanism of therapeutic action
of them for treatment asthma.
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